Opendata, web and dolomites

ContiTRACE SIGNED

Continuous Blood Glucose Monitoring and automated therapeutic closed loop medical device for Intensive Care Units

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ContiTRACE project word cloud

Explore the words cloud of the ContiTRACE project. It provides you a very rough idea of what is the project "ContiTRACE" about.

physiological    infusion    max    offline    penetrate    proves    workload    model    trace    discomfort    50    contitrace    informed    technique    2026    comorbidities    monitoring    patient    increments    public    savings    forecast    14    powered    15    limited    players    diagnostica    decrease    roche    manufacturers    pfizer    infuse    decisions    bgm    companies    samples    blood    optimize    profits    hospital    doctors    headcounts    private    adjustments    newcomers    commercial    17    fluctuations    consumables    twofold    units    business    icus    pharma    manual    minimising    care    days    material    x10    intensive    accesses    5th    safety    economic    icu    death    sell    40    company    risk    insulin    patented    continuous    device    inefficient    sanofi    standardized    300    automatically    distributors    irregular    lifecycle    patients    time    human    caregivers    medical    sensors    return    ai    regulatory    healthcare    invasive    costly    mortality    glucose    keep    self    sasse    careful    aventis    estimates    big    body    investment    2022    intermittent    profil    calibrating    minutes    made    elektronik    glycaemic    levels    safe    automated   

Project "ContiTRACE" data sheet

The following table provides information about the project.

Coordinator
TRACE ANALYTICS GMBH 

Organization address
address: RICHARD WAGNER STRASSE 1-2
city: BRAUNSCHWEIG
postcode: 38106
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TRACE ANALYTICS GMBH DE (BRAUNSCHWEIG) coordinator 50˙000.00

Map

 Project objective

Intensive Care Units (ICUs) require careful monitoring of blood glucose levels and insulin infusion to keep patients within safe physiological levels. Fluctuations of blood glucose are directly related to an increased risk of death and comorbidities. However, blood glucose monitoring (BGM) is still made by intermittent and manual offline analysis of blood samples. This technique proves inefficient (need 17% caregivers time), costly (€300 per patient) and increments mortality in hospital ICUs by 40% due to irregular glucose level adjustments upon measurements. After 15 years of experience in developing glucose monitoring sensors, we at TRACE are taking on our next big step to penetrate the medical device sector with ContiTRACE: an AI powered automated non-invasive medical device for continuous BGM. Our patented ContiTRACE is able to measure glycaemic levels every 2 minutes (automatically) and automatically infuse insulin when needed. It is also capable of self-calibrating and has standardized body accesses, enhancing safety and minimising discomfort for the ICU patient. This will allow 1) caregivers to decrease their workload, 2) doctors to take informed decisions and 3) the healthcare system to optimize their limited human, economic and material resources by providing savings of more than 50% of BGM related cost. Our business model is twofold. We will sell the medical device (5 years lifecycle), and the consumables (max. 4 days duration per set) to private and public hospital ICUs. Our draft forecast (2022-2026) estimates profits of 14.4 M€ with a Return on Investment of 10.7 by the 5th commercial year allowing us to increase x10 our company headcounts in five commercial years. Although newcomers to the medical sector we have the support of key players among regulatory companies (Profil), manufacturers (Sasse Elektronik), pharma companies (Sanofi-Aventis, Pfizer and Roche) and distributors (Care Diagnostica) to take on the BGM challenge.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CONTITRACE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CONTITRACE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More